FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 永泰生物製藥有限公司 呈交日期： 2025年11月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06978 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事 ...

Core Viewpoint - Yongtai Bio-B (06978) has announced significant oversubscription in its rights issue, indicating strong investor interest and confidence in the company's future prospects [1][2] Group 1 - The company received valid acceptances for a total of 92.1758 million rights shares, representing approximately 89.56% of the total 103 million rights shares offered [1] - There were 8 valid applications for additional rights shares, totaling 446 million shares, which is about 433.15% of the total rights shares offered [1] - In total, there were 21 valid acceptances and applications for 538 million rights shares, amounting to approximately 522.71% of the total rights shares offered [1] Group 2 - A total of 435 million rights shares were oversubscribed, which is about 422.71% of the total 103 million rights shares offered [2] - The allocation of additional rights shares was made based on a ratio of approximately 2.41% of the number of additional shares applied for, due to insufficient shares to meet all valid applications [2] - There was no prioritization for applications based on existing shareholdings or for consolidating fractional shares into whole shares [2]

Core Viewpoint - Yongtai Bio-B (06978.HK) has successfully completed its rights issue, with total valid acceptances and applications exceeding the number of shares offered, indicating strong investor interest [1] Group 1: Rights Issue Details - The rights issue was for a total of 102,916,800 shares, with 92,175,828 shares accepted, representing approximately 89.56% of the total offered [1] - Additionally, there were 445,784,230 shares applied for under extra application forms, which is about 433.15% of the total offered shares [1] - In total, there were valid acceptances and applications for 538 million shares, amounting to approximately 522.71% of the total offered shares [1] Group 2: Financial Outcomes - The total proceeds from the rights issue are approximately HKD 257 million, with a net amount expected to be around HKD 252 million after deducting professional fees and other related expenses [1] - The conditions outlined in the rights issue prospectus have been fully met, and the rights issue became unconditional on November 6, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 本 公 告 僅 供 參 考，並 不 構 成 收 購、購 買 或 認 購 本 公 司 證 券 的 邀 請 或 要 約。 Immunotech Biopharm Ltd 永泰生物製藥有限公司 茲提述永泰生物製藥有限公司（「本公司」）日期為2025年10月14日的招股章程（「招 股章程」）。除另有所指外，本公告所用詞彙與招股章程所界定者具有相同涵義。 獲發一(1)股供股股份之基準進行供股 供股結果 及 董 事 會 欣 然 宣 佈，於2025年11月4日（星 期 二）下午四時正（接 納 供 股 股 份 及 繳 付 股 款 以 及 申 請 額 外 供 股 股 份 及 繳 付 股 款 的 最 後 時 限）： – 1 – （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6978） 按於記錄日期 可換股債券換股價及首次公開發售前購股權 ...

致：香港交易及結算所有限公司 公司名稱: 永泰生物製藥有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06978 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.001 | USD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.001 | USD | | 5,000,000 | 本月底法定/註冊股本總額： USD 5,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: ...

Group 1 - The core viewpoint of the article highlights a significant increase in Hong Kong pharmaceutical stocks, with notable gains in specific companies [1] Group 2 - Yongtai Bio surged by 14.94% [1] - Rongchang Bio increased by 5.14% [1] - Other companies such as Kangfang Bio and WuXi AppTec also experienced upward movement [1]

Group 1 - Yongtai Biologics-B (06978.HK) increased by 14.94% [1] - Hepp Pharmaceuticals-B (02142.HK) rose by 5.32% [1] - Rongchang Biologics (09995.HK) gained 5.14% [1] - Yaojie Ankang (02617.HK) saw an increase of 5.02% [1] - Cornerstone Pharmaceuticals-B (02616.HK) experienced a rise of 3.92% [1]

Core Viewpoint - Yongtai Bio-B (06978) announced the appointment of Mr. Cao Ran as a non-executive director and a member of the audit committee, effective from October 16, 2025, while Ms. Yu Xiaohui has resigned from her position as a non-executive director and audit committee member [1] Group 1 - Mr. Cao Ran's appointment as a non-executive director and audit committee member is a significant leadership change for the company [1] - The resignation of Ms. Yu Xiaohui from her roles indicates a shift in the company's governance structure [1]

Core Points - Yongtai Bio-B (06978.HK) announced the appointment of Cao Ran as a non-executive director and a member of the audit committee effective from October 16, 2025 [1] - The company also reported that Yu Xiaohui has resigned from his position as a non-executive director and a member of the audit committee [1]

Core Viewpoint - Yongtai Bio-B (06978) announced the appointment of Mr. Cao Ran as a non-executive director and a member of the audit committee, effective from October 16, 2025, while Ms. Yu Xiaohui has resigned from her position as a non-executive director and a member of the audit committee [1]. Group 1 - Mr. Cao Ran has been appointed as a non-executive director [1] - Mr. Cao Ran will also serve as a member of the audit committee [1] - Ms. Yu Xiaohui has resigned from her role as a non-executive director [1]